Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
Public ClinicalTrials.gov record NCT04123366. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Study identification
- NCT ID
- NCT04123366
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
- Olaparib Drug
- Pembrolizumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2019
- Primary completion
- Jun 28, 2026
- Completion
- Jun 28, 2026
- Last update posted
- Apr 21, 2026
2019 – 2026
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Kirklin Clinic ( Site 0086) | Birmingham | Alabama | 35233 | — |
| Banner MD Anderson Cancer Center ( Site 0049) | Gilbert | Arizona | 85234 | — |
| UC Davis Comprehensive Cancer Center ( Site 0039) | Sacramento | California | 95817 | — |
| San Francisco Oncology Associates ( Site 0085) | San Francisco | California | 94115 | — |
| University of California San Francisco ( Site 0015) | San Francisco | California | 94158 | — |
| Banner MD Anderson Cancer Center ( Site 0092) | Greeley | Colorado | 80631 | — |
| University of Florida ( Site 0078) | Gainesville | Florida | 32608 | — |
| Winship Cancer Institute of Emory University ( Site 0057) | Atlanta | Georgia | 30322 | — |
| Northeast Georgia Medical Center ( Site 0026) | Gainesville | Georgia | 30501 | — |
| Northwest Georgia Oncology Centers PC ( Site 0047) | Marietta | Georgia | 30060 | — |
| Norton Cancer Institute - St. Matthews ( Site 0024) | Louisville | Kentucky | 40207 | — |
| Atlantic Health System ( Site 0046) | Summit | New Jersey | 07901 | — |
| New York Cancer and Blood Specialists-Research Department ( Site 0080) | Port Jefferson Station | New York | 11776 | — |
| University Hospitals Cleveland Medical Center ( Site 0016) | Cleveland | Ohio | 44106 | — |
| The University of Oklahoma Health Sciences Center ( Site 0050) | Oklahoma City | Oklahoma | 73104 | — |
| Parkland Health & Hospital System ( Site 0091) | Dallas | Texas | 75235 | — |
| University of Texas, Southwestern Medical Center ( Site 0004) | Dallas | Texas | 75390 | — |
| University of Texas-MD Anderson Cancer Center ( Site 0087) | Houston | Texas | 77030 | — |
| Utah Cancer Specialists ( Site 0038) | West Valley City | Utah | 84119 | — |
| Inova Schar Cancer Institute ( Site 0008) | Fairfax | Virginia | 22031 | — |
| Northwest Medical Specialties, PLLC ( Site 0007) | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04123366, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04123366 live on ClinicalTrials.gov.